Background: An essential transcription factor linked to tumor growth, the epithelial–mesenchymal transition (EMT), metastasis, and treatment resistance in a number of malignancies is zinc finger E-box-binding homeobox 1 (ZEB1). By virtually screening FDA-approved medications, the current study sought to find possible ZEB1-targeting compounds and assess the main candidate's biological activity in TNBC cells. Methodology: ZEB1 was screened against around 30,000 FDA-approved medications using molecular docking. Molecular dynamics (MD) simulations & protein–ligand interaction tests were used to examine the top-ranked molecule further in order to assess binding stability. MDA-MB-231 cells were employed for preliminary biological validation using the MTT cytotoxicity assay and quantitative RT-PCR measurement of ZEB1 expression. Results and Discussion: Losartan demonstrated the highest docking affinity toward ZEB1 among the investigated compounds, with a docking score of −10.9 kcal/mol. The stability of the protein–ligand complex was further supported by molecular dynamics modeling, which demonstrated persistent protein–ligand interactions during the simulation period. MDA-MB-231 cells exhibited concentration-dependent cytotoxicity following Losartan treatment, with an IC50 of 115 µg/mL. Quantitative RT-PCR analysis showed a numerical decrease in normalized ZEB1 mRNA expression in Losartan-treated cells compared with untreated controls, with a fold change of 0.38; however, this difference was not statistically significant (p = 0.5755). Conclusion: The computational findings support the potential interaction of Losartan with ZEB1, while the preliminary in vitro results demonstrated cytotoxic activity, and a numerical change in normalized ZEB1 mRNA expression did not reach statistical significance. This study highlights the potential of drug-repurposing approaches for identifying candidate compounds for further investigation in ZEB1-associated cancer pathways.